Dr Paul Joyce is Head of the Translational Nanomedicine & Biotherapeutics Group at the University of South Australia where his research focuses on harnessing drug delivery approaches for transforming therapeutic outcomes across a wide range of diseases, including cancer, mental health, and antimicrobial resistance. Working at the interface of materials science and drug development, Dr Joyce engages closely with key stakeholders who enable clinical and commercial translation of his research, including the pharmaceutical industry, clinicians, and health consumers. Dr Joyce’s leadership within this field is evidenced through his publication of over 70 peer reviewed papers in leading international journals, 3 book chapters, and 3... Read more
About me
Dr Paul Joyce is Head of the Translational Nanomedicine & Biotherapeutics Group at the University of South Australia where his research focuses on harnessing drug delivery approaches for transforming therapeutic outcomes across a wide range of diseases, including cancer, mental health, and antimicrobial resistance. Working at the interface of materials science and drug development, Dr Joyce engages closely with key stakeholders who enable clinical and commercial translation of his research, including the pharmaceutical industry, clinicians, and health consumers. Dr Joyce’s leadership within this field is evidenced through his publication of over 70 peer reviewed papers in leading international journals, 3 book chapters, and 3 granted international patents for novel nanomedicine inventions. Further, Dr Joyce is a Director of the Australian Controlled Release Society, the leading society for delivery science, and has been awarded over $9M in funding to support his research activities, including serving as a current Hospital Research Foundation Fellow and Cancer Council SA Fellow.
About me
About me
Date | Title |
---|---|
14/12/2018 |
Could eating DIRT be the cure for obesity?, https://www.dailymail.co.uk/health/article-6493241/How-pill-mud-cure-obesity-soaking-fat-stop-body-absorbing-it.html |
About me
Doctor of Philosophy University of South Australia
Postdoctoral Research Fellow - Chalmers University of Technology, 2017 - 2019
Doctor of Philosophy (Pharmacy) - University of South Australia, 2012 - 2016
Bachelor of Engineering (Honours) (Pharmaceutical and Chemical) - University of Adelaide, 2007 - 2011
Designing, engineering and applying innovative drug delivery solutions that overcome key biopharmaceutical challenges for the benefit of the wider community. Cutting edge biophysical and synthesis techniques are employed to develop novel strategies and technologies that are well-positioned for rapid clinical translation.
Research
Excludes commercial-in-confidence projects.
Evaluating protein supplementation in ulcerative colitis (SUPP UC), Central Adelaide Local Health Network Incorporated, 27/05/2025 - 06/01/2028
Omega-3 Fatty Acid Quantification in Patient Plasma Samples, Pharmako Biotechnologies Pty Ltd, 15/10/2024 - 27/08/2025
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2019 |
19
18
120
|
2019 |
Open access
94
85
4
|
2017 |
22
20
5
|
2016 |
34
34
|
2015 |
30
28
4
|
Year | Output |
---|---|
2025 |
Open access
|
2025 |
Open access
2
2
|
2025 |
Open access
|
2025 |
Open access
4
5
|
2025 |
Open access
1
1
|
2024 |
Open access
18
14
3
|
2024 |
Open access
5
71
|
2024 |
Open access
1
2
|
2024 |
Open access
87
|
2024 |
Open access
8
7
3
|
2024 |
Open access
2
|
2024 |
Open access
10
8
44
|
2024 |
Open access
2
4
15
|
2024 |
Open access
40
130
|
2024 |
Open access
4
4
|
2024 |
Open access
3
2
|
2024 |
Open access
11
10
85
|
2024 |
Open access
1
|
2024 |
Open access
4
4
|
2024 |
Open access
4
5
1
|
2024 |
Open access
5
4
3
|
2024 |
Open access
|
2024 |
5
6
1
|
2024 |
Open access
5
5
4
|
2024 |
1
1
|
2023 |
Open access
5
4
64
|
2023 |
Open access
7
9
|
2023 |
Open access
19
19
11
|
2023 |
Open access
13
10
|
2023 |
Open access
41
|
2023 |
7
6
|
2023 |
Open access
24
22
5
|
2023 |
Open access
11
11
21
|
2023 |
Open access
27
25
4
|
2023 |
Open access
22
22
8
|
2023 |
Open access
10
7
4
|
2023 |
16
19
|
2023 |
7
8
5
|
2022 |
5
5
3
|
2022 |
14
13
66
|
2022 |
Open access
10
10
121
|
2022 |
Open access
262
|
2022 |
Open access
7
9
3
|
2022 |
Open access
9
7
333
|
2022 |
Open access
9
8
1
|
2021 |
Open access
8
8
|
2021 |
Open access
29
28
4
|
2021 |
Open access
10
10
4
|
2021 |
8
8
1
|
2021 |
69
66
11
|
2021 |
Open access
9
9
10
|
2020 |
Open access
10
10
2
|
2020 |
12
12
3
|
2020 |
23
19
4
|
2020 |
7
6
1
|
2020 |
17
13
|
2020 |
49
47
2
|
2020 |
Open access
8
8
|
2020 |
Open access
16
16
13
|
2019 |
Open access
17
17
|
2019 |
19
18
120
|
2019 |
14
13
2
|
2019 |
Open access
94
85
4
|
2019 |
43
35
|
2018 |
18
15
4
|
2018 |
22
20
7
|
2018 |
23
21
|
2018 |
29
28
2
|
2017 |
Open access
10
9
|
2017 |
22
20
5
|
2017 |
Open access
18
17
|
2016 |
Open access
38
37
|
2016 |
34
34
|
2016 |
31
29
|
2016 |
29
28
1
|
2016 |
36
37
|
2015 |
23
23
|
2015 |
30
28
4
|
2014 |
Open access
50
50
|
Patents
Prestidge & Joyce, ‘Novel Drug Delivery Composition Comprising Polymer-Lipid Hybrid Microparticles’ (PCT/AU2016/000080)
Research
Designing, engineering and applying innovative drug delivery solutions that overcome key biopharmaceutical challenges for the benefit of the wider community. Cutting edge biophysical and synthesis techniques are employed to develop novel strategies and technologies that are well-positioned for rapid clinical translation.
Research
Details | Registry | Status |
---|---|---|
Drug delivery composition comprising polymer-lipid hybrid microparticles Prestidge, Clive Allan; Joyce, Paul Matthew |
Australia | Filed |
External engagement & recognition
Organisation | Country |
---|---|
AstraZeneca (United Kingdom) | UNITED KINGDOM |
Brigham and Women's Hospital | UNITED STATES |
Central Adelaide Local Health Network Incorporated | AUSTRALIA |
Chalmers University of Technology | SWEDEN |
CSIRO Australia (Commonwealth Scientific Industrial Research organisation) | AUSTRALIA |
Free University of Amsterdam | NETHERLANDS |
Glantreo Limited | IRELAND |
Hebrew University of Jerusalem | ISRAEL |
Humanitas University | ITALY |
Johnson & Johnson | UNITED STATES |
King's College London | UNITED KINGDOM |
Macquarie University | AUSTRALIA |
Massey University | NEW ZEALAND |
Monash University | AUSTRALIA |
Oulun Yliopisto | FINLAND |
Radboud University Nijmegen | NETHERLANDS |
RMIT University | AUSTRALIA |
Russian Academy of Sciences | RUSSIAN FEDERATION |
SA Pathology | AUSTRALIA |
Saarland University | GERMANY |
South Australian Health and Medical and Research Institute (SAHMRI) | AUSTRALIA |
Stellenbosch University | SOUTH AFRICA |
Syrian-Lebanese Hospital (Brazil) | BRAZIL |
Tehran University of Medical Sciences | IRAN |
The Bowel Clinic London UK | UNITED KINGDOM |
The Queen Elizabeth Hospital | AUSTRALIA |
Umeå University | SWEDEN |
University of Adelaide | AUSTRALIA |
University of Copenhagen | DENMARK |
University of Gothenburg | SWEDEN |
University of Groningen | NETHERLANDS |
University of Manitoba | CANADA |
University of New South Wales | AUSTRALIA |
University of Parma | ITALY |
University of Porto | PORTUGAL |
University of Santiago de Compostela | SPAIN |
University of South Australia | AUSTRALIA |
University of the Western Cape | SOUTH AFRICA |
University of Toronto | CANADA |
University of Trieste | ITALY |
Uppsala University | SWEDEN |
Vaxine Pty Ltd | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Chair of Frontiers in Bio-Nano Science 2021ARC Centre of Excellence in Convergent Bio-Nano Science and Technology |
2021 |
ECR RepresentativeAustralasian Society for Biomaterials and Tissue Engineering |
2021 |
MemberAustralian Nanotechnology Network (ANN) |
2021 |
MemberAmerican Association of Pharmaceutical Scientists |
2021 |
MemberAustralasian Colloid and Interface Society |
2021 |
MemberControlled Release Society |
2021 |
MemberEuropean Colloid & Interface Society |
2021 |
Outreach Committee MemberARC Centre of Excellence in Convergent Bio-Nano Science and Technology |
2021 |
STEM Professional in SchoolsCommonwealth Scientific and Industrial Research Organisation (CSIRO) |
2021 |
Topic EditorMembranes |
2021 |
Topic EditorAntibiotics |
2021 |
YourVoice Lung AdvocateLung Foundation Australia |
2021 |
Chair of Frontiers in Bio-Nano Science 2021ARC Centre of Excellence in Convergent Bio-Nano Science and Technology |
2020 |
ECR RepresentativeAustralasian Society for Biomaterials and Tissue Engineering |
2020 |
Keynote LectureRoyal Australian Chemical Institute (RACI) Chemistry Teachers Association |
2020 |
MemberAmerican Association of Pharmaceutical Scientists |
2020 |
MemberAustralasian Colloid and Interface Society |
2020 |
MemberControlled Release Society |
2020 |
MemberAustralian Nanotechnology Network (ANN) |
2020 |
MemberEuropean Colloid & Interface Society |
2020 |
Outreach Committee MemberARC Centre of Excellence in Convergent Bio-Nano Science and Technology |
2020 |
STEM Professional in SchoolsCommonwealth Scientific and Industrial Research Organisation (CSIRO) |
2020 |
Topic EditorMembranes |
2020 |
Topic EditorAntibiotics |
2020 |
YourVoice Lung AdvocateLung Foundation Australia |
2020 |
MemberEuropean Colloid & Interface Society |
2019 |
MemberAmerican Association of Pharmaceutical Scientists |
2019 |
MemberAustralasian Colloid and Interface Society |
2019 |
MemberAustralian Nanotechnology Network (ANN) |
2019 |
MemberAustralasian Pharmaceutical Science Association (APSA) |
2019 |
MemberControlled Release Society |
2019 |
Postdoctoral Research FellowshipAforsk Foundation |
2019 |
STEM Professional in SchoolsCommonwealth Scientific and Industrial Research Organisation (CSIRO) |
2019 |
Topic EditorAntibiotics |
2019 |
Keynote PresentationInternational Conference on Advanced Nano Materials |
2018 |
MemberControlled Release Society |
2018 |
MemberEuropean Colloid & Interface Society |
2018 |
MemberAmerican Association of Pharmaceutical Scientists |
2018 |
MemberAustralasian Pharmaceutical Science Association (APSA) |
2018 |
MemberAustralasian Colloid and Interface Society |
2018 |
Postdoctoral Research FellowshipAforsk Foundation |
2018 |
Best ECR Oral PresentationEuroFed Lipid Conference |
2017 |
Keynote LectureEuropean Colloid and Interface Science Symposium |
2017 |
MemberAustralasian Colloid and Interface Society |
2017 |
MemberEuropean Colloid & Interface Society |
2017 |
MemberAmerican Association of Pharmaceutical Scientists |
2017 |
MemberControlled Release Society |
2017 |
Postdoctoral Research FellowshipAforsk Foundation |
2017 |
MemberAustralasian Colloid and Interface Society |
2016 |
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
110496 - Lipid-based Nanocarrier Enabled Delivery for Improved T-cell Immunotherapy | Current |
110502 - Developing advanced oral delivery formulations for treating leukemia | Current |
111602 - Improving mental health therapies by targeting the gut microbiome | Current |
460- Gut-Targeted Nanomedicines for Overcoming the Metabolic Side Effects of Antipsychotics | Current |
Conquering antimicrobial resistant Gram-negative bacteria to address unmet clinical needs | Current |
Design of Lipid Nanoparticles (LNPs) for mRNA-Based Cancer Vaccines | Current |
Developing advanced oral delivery systems for antiviral drugs | Current |
Development of a safe biomaterial-based therapy for obesity | Current |
Engineering multifunctional hybrid materials for effective modulation of the gut microbiome | Current |
Exploring the impact of formulation design on PUFA pharmacokinetics and biodistribution | Current |
Formulation Design and Development of Oral Chemotherapeutic Prodrugs: In Vitro, In Vivo, and In Silico Characterisation and Evaluation | Current |
Improving the efficacy of lung cancer therapies through targeted nanomedicine | Current |
Lipid-based formulations to overcome challenges in oral drugdelivery | Current |
Microbial amyloids of gut-microbiome and aging paradigms of protein aggregation | Current |
Optimising treatment of haematological malignancies through the development of evidence-based dose individualisation strategies | Current |
Regulating vitamin D-gut microbiota interactions to prevent chemotherapy-induced mucositis | Current |
Therapeutic targeting of Cyp24a1 to mitigate 5-Fluorouracil-induced gastrointestinal mucositis | Current |
Understanding the Biological Performance of Plant Derived Fats and Proteins - Towards Improved Meat Analogues | Current |
Beyond the gastrointestinal cell layer: replication of the complex oral absorption barrier through enhanced in vitro models for nanoparticulate oral protein delivery | Completed |
Lipid liquid crystalline nanoparticles: a delivery system for antimicrobial photodynamic therapy | Completed |
Overcoming biological barriers in treating intracellular infections using lipid-based nanoparticles | Completed |
Polymer-lipid hybrid microparticles enhance the intracellular uptake and activity of rifampicin against bacterially infected macrophages | Completed |